Literature DB >> 3292702

Comparison of 125I-SCH 23982 and [3H]SCH 23390 as ligands for the D-1 dopamine receptor.

C P Manik1, P B Molinoff, P McGonigle.   

Abstract

125I-SCH 23982, an antagonist with high affinity and selectivity for the D-1 subtype of dopamine receptors, has recently been synthesized. Densities of D-1 receptors in rat brain obtained from autoradiographic studies using this iodinated ligand are 5- to 10-fold less than densities reported with tritiated analogues such as [3H]SCH 23390. A direct comparison of these two ligands using striatal homogenates confirmed this discrepancy. One explanation for this difference is that 125I-SCH 23982 labels a subset of the sites labeled by [3H]SCH 23390. However, the distributions of sites labeled by the ligands in autoradiograms of horizontal sections of rat brain were virtually identical. Furthermore, 127I-SCH 23982 displaced 100% of the specifically bound [3H]SCH 23390 in striatal homogenates with a Hill coefficient of approximately 1. These results are not consistent with the existence of a subset of receptors recognized by 125I-SCH 23982 and suggest that both ligands label the same population of receptors. An alternative explanation for the discrepancy in Bmax values is that an unlabeled inhibitor is present in commercial preparations of 125I-SCH 23982. When all of the solvent (including any volatile inhibitors) was removed from commercial preparations of 125I-SCH 23982 prior to use in radioligand binding experiments, the discrepancy in Bmax values was eliminated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292702     DOI: 10.1111/j.1471-4159.1988.tb01051.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  1 in total

1.  Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists.

Authors:  Benjamin R Chemel; Lisa A Bonner; Val J Watts; David E Nichols
Journal:  Mol Pharmacol       Date:  2012-02-14       Impact factor: 4.436

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.